Rate of ESRD Exceeds Mortality among African Americans with Hypertensive Nephrosclerosis

被引:47
作者
Alves, Tahira P. [1 ]
Wang, Xuelei [2 ]
Wright, Jackson T., Jr. [3 ,4 ]
Appel, Lawrence J. [5 ]
Greene, Tom [6 ]
Norris, Keith [7 ]
Lewis, Julia [8 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Div Nephrol, Dept Med, San Antonio, TX 78229 USA
[2] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[3] Univ Hosp Case Med Ctr, Dept Med, William T Dahms Clin Res Unit, Cleveland, OH USA
[4] Univ Hosp Case Med Ctr, Clin Hypertens Program, Cleveland, OH USA
[5] Johns Hopkins Med Inst, Dept Med Epidemiol & Int Hlth Human Nutr, Baltimore, MD 21205 USA
[6] Univ Utah, Div Epidemiol, Dept Biostat, Salt Lake City, UT USA
[7] Charles R Drew Univ Med & Sci, Clin Res Ctr, Dept Res, Lynwood, CA USA
[8] Vanderbilt Univ, Dept Med, Div Nephrol, Nashville, TN USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2010年 / 21卷 / 08期
基金
美国国家卫生研究院;
关键词
CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR-DISEASE; RACIAL-DIFFERENCES; RENAL OUTCOMES; RISK-FACTOR; DISPARITIES; DEATH; EPIDEMIOLOGY; PROGRESSION; POPULATION;
D O I
10.1681/ASN.2009060654
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In several studies, patients with CKD seemed to be at greater risk for dying from cardiovascular disease (CVD) than reaching ESRD. The purpose of this study was to compare incident ESRD rates with rates of total mortality, CVD death, and a CVD composite (CVD mortality and CVD hospitalization) among participants who had hypertensive nephrosclerosis and were enrolled in the African American Study of Kidney Disease and Hypertension (AASK). The study period included the AASK trial phase (1996 through 2001) and a subsequent cohort phase (2002 through 2007) The AASK enrolled 1094 participants. Of the 764 participants who completed the trial phase without an event, 691 (90%) enrolled in the cohort phase. During 11 years of follow-up, there were 59 CVD-related deaths and 118 non-CVD-related deaths. The rate of ESRD (3.9/100 patient-years) was significantly higher than the rates of total mortality (2.2/100 patient-years), CVD mortality (0.8/100 patient-years), and the CVD composite (3 2/100 patient-years). The incidence rate ratio of ESRD to CVD mortality was 5.0. The rate of ESRD consistently exceeded the various mortality rates across most of the subgroups defined by age, gender, income, education, previous CVD, baseline urine protein excretion, and baseline estimated GFR. In conclusion, AASK participants were more likely to reach ESRD than to die.
引用
收藏
页码:1361 / 1369
页数:9
相关论文
共 28 条
[1]   Racial and ethnic disparities in end-stage kidney failure - Survival paradoxes in African-Americans [J].
Agodoa, Lawrence ;
Eggers, Paul .
SEMINARS IN DIALYSIS, 2007, 20 (06) :577-585
[2]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[3]  
[Anonymous], 2008, Am J Kidney Dis, V51, pS1
[4]  
Antihypertensive T., 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI [10.1001/jama.288.23.2981, DOI 10.1001/JAMA.288.23.2981]
[5]   Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans [J].
Appel, Lawrence J. ;
Wright, Jackson T., Jr. ;
Greene, Tom ;
Kusek, John W. ;
Lewis, Julia B. ;
Wang, Xuelei ;
Lipkowitz, Michael S. ;
Norris, Keith C. ;
Bakris, George L. ;
Rahman, Mahboob ;
Contreras, Gabriel ;
Rostand, Stephen G. ;
Kopple, Joel D. ;
Gabbai, Francis B. ;
Schulman, Gerald I. ;
Gassman, Jennifer J. ;
Charleston, Jeanne ;
Agodoa, Lawrence Y. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (08) :832-839
[6]   The rationale and design of the AASK Cohort Study [J].
Appel, LJ ;
Middleton, J ;
Miller, ER ;
Lipkowitz, M ;
Norris, K ;
Agodoa, LY ;
Bakris, G ;
Douglas, JG ;
Charleston, J ;
Gassman, J ;
Greene, T ;
Jamerson, K ;
Kusek, JW ;
Lewis, JA ;
Phillips, RA ;
Rostand, SG ;
Wright, JT .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :S166-S172
[7]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]   Incidence of end-stage renal disease and death among insured African Americans with chronic kidney disease [J].
Derose, Stephen F. ;
Rutkowski, Mark P. ;
Levin, Nathan W. ;
Liu, In-Lu A. ;
Shi, Jiaxiao M. ;
Jacobsen, Steven J. ;
Crooks, Peter W. .
KIDNEY INTERNATIONAL, 2009, 76 (06) :629-637
[9]   Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States medicare population, 1998 to 1999 [J].
Foley, RN ;
Murray, AM ;
Li, SL ;
Herzog, CA ;
McBean, AM ;
Eggers, PW ;
Collins, AJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :489-495
[10]   Clinical epidemiology of cardiovascular disease in chronic renal disease [J].
Foley, RN ;
Parfrey, PS ;
Sarnak, MJ .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :S112-S119